Company: AZN
Filing Date: 2025-03-31
Form Type: 6-K
Source: 0001654954-25-003590
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-03-31
Form: 6-K
Chunk 4
---
O/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @ AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### References
1. Lymphoma Research Foundation. Mantle Cell Lymphoma. Available at: https://lymphoma.org/aboutlymphoma/nhl/mcl/ . Accessed March 2025.

2. National Organization for Rare Disorders. Mantle Cell Lymphoma. Available at: https://rarediseases.org/rare-diseases/mantle-cell-lymphoma/ . Accessed March 2025.

3. AstraZeneca 2024. Q3 2024 Financial Results. Available at: https://www.astrazeneca.com/investor-relations.html . Accessed March 2025.

4. Cheah C, Seymour J, Wang ML. Mantle cell lymphoma. J Clin Oncol . 2016;34(11):1256-1269. doi: 10.1200/JCO.2015.63.5904.

5. Lynch DT, Koya S, Acharya U, et al. Mantle Cell Lymphoma. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536985 . Accessed March 2025.

6. ClinicalTrials.gov. A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL. Available at: https://clinicaltrials.gov/study/NCT02972840. Accessed March 2025.

7. Luque-Paz D, et al. B-cell malignancies and COVID-19: a narrative review. Clin Microbiology and Infection . 2023; 29(332-337).

8. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol . 2016;9(21).

#### Adrian Kemp